Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours
- PMID: 8605087
- PMCID: PMC2074348
- DOI: 10.1038/bjc.1996.98
Preclinical in vivo efficacy of two 9-dihydrotaxane analogues against human and murine tumours
Abstract
Two 9-dihydrotaxane analogues were synthesised and tested for in vitro potency and in vivo efficacy against murine and human tumour xenografts in mice. The in vitro potency of 9-dihydrotaxol (9-DH-t) and 10-deacetyl-9-dihydrotaxol (10-DeAc-9-DH-t) was generally less than that of paclitaxel against human and murine tumour cells. However, both analogues were at least 20-fold more soluble than paclitaxel in water. The analogues yielded cure rates > or = 60% against human MX-1 solid tumour xenografts in mice, compared with a cure rate of 10% for mice treated with paclitaxel. Both of the analogues were more effective than paclitaxel for treatment of murine M109 solid tumour in mice. 10-DeAc-9-DH-t was as effective as paclitaxel against murine B16 ascites tumour, while 9-DH-t was less effective. Both 10-DeAc-9-DH-t and 9-DH-t were demonstrably less toxic than paclitaxel. At equal dosages 9-DH-t produced serum concentrations greater than paclitaxel, while 10-DeAc-9-DH-t yielded serum concentrations less than paclitaxel. However, the decrease in toxicity of 9-DH-t and 10-DeAc-9-DH-t allowed a 4-fold increase in daily dosage. These two 9-dihydrotaxane analogues yielded favourable preclinical data and demonstrated good potential for further development.
Similar articles
-
Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.Clin Cancer Res. 1999 Apr;5(4):891-7. Clin Cancer Res. 1999. PMID: 10213226
-
Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.Cancer Chemother Pharmacol. 2000;46(3):246-50. doi: 10.1007/s002800000137. Cancer Chemother Pharmacol. 2000. PMID: 11021743
-
Preclinical antitumor activity of water-soluble paclitaxel derivatives.Cancer Chemother Pharmacol. 1997;39(6):486-92. doi: 10.1007/s002800050603. Cancer Chemother Pharmacol. 1997. PMID: 9118459
-
The taxoids. Comparative clinical pharmacology and therapeutic potential.Drugs. 1998 Jan;55(1):5-30. doi: 10.2165/00003495-199855010-00002. Drugs. 1998. PMID: 9463787 Review.
-
[Taxoids: structural and experimental properties].Bull Cancer. 1995 Apr;82(4):249-64. Bull Cancer. 1995. PMID: 10846536 Review. French.
Cited by
-
Taxol biosynthesis and molecular genetics.Phytochem Rev. 2006 Feb;5(1):75-97. doi: 10.1007/s11101-005-3748-2. Phytochem Rev. 2006. PMID: 20622989 Free PMC article.
-
Comparative metabolomic analysis reveals the variations in taxoids and flavonoids among three Taxus species.BMC Plant Biol. 2019 Nov 29;19(1):529. doi: 10.1186/s12870-019-2146-7. BMC Plant Biol. 2019. PMID: 31783790 Free PMC article.
-
Risks and benefits of taxanes in breast and ovarian cancer.Drug Saf. 2000 Nov;23(5):401-28. doi: 10.2165/00002018-200023050-00005. Drug Saf. 2000. PMID: 11085347 Review.
-
A natural food sweetener with anti-pancreatic cancer properties.Oncogenesis. 2016 Apr 11;5(4):e217. doi: 10.1038/oncsis.2016.28. Oncogenesis. 2016. Retraction in: Oncogenesis. 2023 Mar 16;12(1):15. doi: 10.1038/s41389-023-00461-7. PMID: 27065453 Free PMC article. Retracted.
-
Progress in the development of alternative pharmaceutical formulations of taxanes.Invest New Drugs. 2001 May;19(2):143-53. doi: 10.1023/a:1010682916808. Invest New Drugs. 2001. PMID: 11392448 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources